Several medications commonly prescribed for oral mucosal administration are actually intended for transdermal application. Many conditions affecting the oral mucosa require frequent or long-term treatments and some treatments are systemically applied.
Clinical resistance and patient intolerance of such treatments may develop. There is thus a constant need to address these problems through the development of less side-effect prone drugs.
‘Topical application of doxycycline was very effective in promoting healing of mucosal lesions including Aphthous stomatitis which are small ovoid ulcers restricted to the mouth.’
Researchers at the University of Iceland have developed several new formulations for topical treatments of oral mucosal conditions and carried out appropriate clinical trials.
The main area of this research has been the inhibition of matrix metallo-proteinase activity using topical doxycycline, initially in order to treat aphthous ulceration.
Aphthous stomatitis (RAS) is a common condition, restricted to the mouth, that typically starts in childhood or adolescence as recurrent small, round, or ovoid ulcers with circumscribed margins.
The anti-microbial compound monocaprin was also tested for activity against herpes virus and, in combination with doxycycline, was developed in an active formulation for treating cold sores (canker sores). Monocaprin also has anti-candidal activity that has been evaluated among geriatric patients with denture stomatitis.
Topical application of doxycycline was very effective in promoting healing of mucosal lesions. Monocaprin reduced counts of Candida rapidly and significantly. The results of these clinical studies have been very promising when compared to the conventional treatments available in Iceland and abroad.
Stability of the active components has recently been effectively addressed and current research is aimed at different types of drug delivery systems in order to optimize drug delivery to the local mucosal site. This includes drug release time and muco-adhesive capacity of the formulation, thereby attempting to develop more disease-specific drug delivery systems.